{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.0","upperLimit":"294.0","value":"170.0"},{"comment":"There were an insufficient number of participants with events and therefore the Median and Upper limit of the 95% CI for the duration of response could not be calculated.","groupId":"OG001","lowerLimit":"84.0","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"115.0","upperLimit":"311.0","value":"280.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"139"}],"units":"Participants"}],"description":"Duration of response and time to response were summarized. A Kaplan-Meier analysis of time to progression was performed, including estimation and 95% confidence interval of the median time to progression and progression-free survival.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG000","title":"Bexarotene Exposed"},{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG001","title":"Bexarotene Naive"},{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG002","title":"All Participants"}],"paramType":"MEDIAN","populationDescription":"The analysis was performed in FAS population was defined according to the intention-to-treat principle. This population will include all participants enrolled into the study.","reportingStatus":"POSTED","timeFrame":"Baseline up to Cycle 12, an average of 12 months","title":"Duration of Response (DOS)","type":"SECONDARY","unitOfMeasure":"Days"}